News | Patient Monitors | June 09, 2015

Smart Vascular Graft Wins Best in Show at Start-up Investors' Event

Graft has embedded flow sensors to detect stenosis

June 9, 2015 - Start-up company GraftWorx was chosen as "Best in Show" at the Mid-Atlantic Bio Angels (MABA) 1st Pitch Life Science event, an investors' conference held in New York in June. Graftworx is a medical device company that has developed a unique peripheral vascular prosthetic bypass graft incorporating a sensor that can alert physicians when blood flow in the graft is blocked due to restenosis. 

Each year, millions of lives are threatened by peripheral artery disease (PAD), where plaque restricts blood flow and can lead to limb loss and organ failure, said David J. Kuraguntla, CEO of GraftWorx. Surgical bypass grafts are effective at restoring blood flow, but peripheral vessels have a very high rate of in-stent restenosis, which can lead to expensive, debilitating outcomes if it goes undetected.

To solve this problem, GraftWorx has designed smart vascular prosthetics with a built in sensor that can detect and accurately measure restenosis formation and progress, along with monitoring other hemodynamic parameters of the patient. Well before the prosthetic has reached failure, it should automatically alert the clinician so that
they can bring in the patient for a simple, safe, outpatient angioplasty. This allows both the clinician and patient to avoid the catastrophic results of undetected prosthetic failure, such as an amputation or prosthetic replacement.
 
"GraftWorx is grateful to have had the opportunity to participate in the 1st Pitch Life Sciences event," Kuraguntla said. "The candid feedback from the investors will help us hone in on the key elements of our business model and the great questions from the audience will help us clarify our story."
 
"Graftworx stood out in its potential to disrupt the market for treatments in its area, in this case, peripheral arterial disease," said Stephen Goodman, partner at Pryor Cashman, and co-founder of Mid Atlantic Bio Angels, which puts on the 1st Pitch events. "The audience recognized both the persuasiveness of the company's business plan and the mastery of the presenter."
 
"The company's ground-breaking concept of adding a flow sensor to bypass grafts is simple in concept, but it's technically difficult to put all the necessary pieces in place to actually achieve," added Arthur Klausner, CEO of both Jade Therapeutics and Gem Therapeutics as well as one of the 1st Pitch Life Sciences event judges. "They seem to be well on their way toward meeting this goal."
 
The Graftworx prosthesis is monitors the characteristic of blood flow through the lumen of the graft. The sensor can be covered with another tubular prosthesis or by a layer of material in order to insulate the sensor from the fluid flow. A pocket may be formed between the tubular prosthesis and the adjacent layer of material or prosthesis and the sensor may be disposed in the pocket.
 
At a 1st Pitch event, early stage life sciences and healthcare companies make a 15-minute presentation to a panel of experienced life science investors and consultants, followed by a 15-minute audience Q&A. However, where actual investors would then ask the presenting company to leave the room during their subsequent discussion, presenting companies at 1st Pitch are invited to hear the panel constructively critique the company's presentation, business model and perceived viability in the market. 
 
The Mid Atlantic Bio Angels is a group of active angel investors, which meets in New York City monthly to hear from pre-screened early-stage life science companies. MABA's goal is to create an environment where the depth of investors' knowledge coupled with the pre-screening of presenting companies enhances the potential for meaningful investment.
 
For more information: www.graftworx.com
 

Related Content

News | Cardiovascular Surgery

November 23, 2021 — A novel device called venous external support (VEST) may lead to increased longevity and durability ...

Home November 23, 2021
Home
News | Cardiovascular Surgery

November 22, 2021 — The Minneapolis Heart Institute Foundation (MHIF) announced the publication of research showing ...

Home November 22, 2021
Home
News | Cardiovascular Surgery

November 18, 2021 — Moderna Inc. announced positive data from the AstraZeneca-led Phase 2 (EPICCURE) study evaluating ...

Home November 18, 2021
Home
News | Cardiovascular Surgery

November 18, 2021 — People who are on the antiplatelet medication ticagrelor and need coronary artery bypass surgery may ...

Home November 18, 2021
Home
Feature | Cardiovascular Surgery | By Noam Emanuel, Ph.D.

Surgical Site Infection (SSI) prevention remains a high priority for cardiac surgeons whose heroic efforts can be ...

Home June 24, 2021
Home
News | Cardiovascular Surgery

April 5, 2021 — Smidt Heart Institute transplant surgeons Dominic Emerson, M.D., and Pedro Catarino, M.D. know how to be ...

Home April 05, 2021
Home
News | Cardiovascular Surgery

March 30, 2020 — Patients undergoing coronary bypass graft (CAGB) surgery lived longer and had better outcomes when ...

Home March 30, 2020
Home
News | Cardiovascular Surgery

February 27, 2020 — The U.S. Food and Drug Administration (FDA) sent a safety communication this week to healthcare to ...

Home February 27, 2020
Home
News | Cardiovascular Surgery

October 23, 2019 — Proactive administration of amiodarone to patients recovering from a common heart surgery shows ...

Home October 23, 2019
Home
News | Cardiovascular Surgery

October 17, 2019 — W. L. Gore & Associates Inc. will support a new Society for Vascular Surgery (SVS) initiative to ...

Home October 17, 2019
Home
Subscribe Now